Once registered, you can:

  • - Read additional free articles each month
  • - Comment on articles and featured creative work
  • - Get our curated newsletters delivered to your inbox

By registering you agree to our privacy policy, terms & conditions and to receive occasional emails from Ad Age. You may unsubscribe at any time.

Are you a print subscriber? Activate your account.

Schering wins ruling in fight over Zyrtec claims

Published on .

Schering-Plough Corp., Madison, N.J., marketer of the top-selling prescription allergy relief product Claritin, won a favorable court ruling Aug. 18 in its legal fight over ad claims made by rival allergy product Zyrtec. The U.S. Court of Appeals in New York overruled a lower court ruling that barred certain evidence in Schering-Plough's case against Pfizer and UCB, co-marketers of Zyrtec. Schering contends the Zyrtec marketers have falsely claimed that their product does not have a significant sedative effect. Schering-Plough promotes Claritin as a non-sedating allergy relief product. The appeals court sent the dispute back to the lower court for further action. Pfizer recently shifted its Zyrtec advertising account to Deutsch, New York, after a review.

Copyright August 1999, Crain Communications Inc.

Most Popular
In this article: